<DOC>
	<DOCNO>NCT00923611</DOCNO>
	<brief_summary>The purpose study evaluate antihypertensive efficacy tolerability 8 week treatment Fimasartan ( BR-A-657-K ) 20 , 60 , 120 , 240 mg placebo patient mild moderate essential hypertension determine adequate antihypertensive dosage later clinical study .</brief_summary>
	<brief_title>Antihypertensive Efficacy Tolerability Determine Adequate Antihypertensive Dosage Fimasartan Mild Moderate Essential Hypertension Patients</brief_title>
	<detailed_description>Fimasartan ( BR-A-657-K ) , selective blocker AT1 receptor subtype , show rapid potent antihypertensive effect many hypertensive model . Phase I study , Fimasartan ( BR-A-657-K ) 20mg ~ 480mg single dose healthy subject , demonstrate Fimasartan ( BR-A-657-K ) safe well tolerate . Another phase I study , Fimasartan ( BR-A-657-K ) 120mg 360mg dose 7 day , also show Fimasartan ( BR-A-657-K ) safe tolerable though one temporal adverse event observe high dose . A randomized , double-blind , placebo-controlled , parallel group , clinical study conduct evaluate antihypertensive efficacy tolerability determine adequate antihypertensive dosage Fimasartan ( BR-A-657-K ) patient mild moderate essential hypertension . Approximately 182 patient enrol 12 month 8 center nationwide . After 2 week placebo run-in period , subject randomize one follow 5 group . Subjects take test/control drug 8 week treatment period . If subject take antihypertensive medication screen , subject 1 week wash-out period . Group I : Placebo , Group II : Fimasartan 20 mg , Group III : Fimasartan 60 mg , Group IV : Fimasartan 120 mg , Group V : Fimasartan 240 mg ,</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>Mild moderate essential hypertension : sit diastolic blood pressure measure Screening Baseline ( Day1 ) 95~114 mmHg inclusive difference sit diastolic blood pressure measure Day 14 Baseline ( Day1 ) 7mmHg . Subjects agree participate sudy give write informed consent Subjects consider understand study , cooperative , able followedup end study The sit DBP le 94mmHg 115mmHg severe hypertensive patient sit systolic blood pressure 200mmHg Patients secondary hypertension Patients severe renal ( Creatinine 1.5 time upper limit normal ) , gastrointestinal , hematological hepatic ( AST , ALT 2 twice upper limit normal ) disease etc . might affect absorption , disposition , metabolism excretion drug Patients postural hypotension Patients sever insulin dependent diabetes mellitus uncontrolled diabetes mellitus ( HbA1c &gt; 9 % , regimen change oral hypoglycemic agent within 3 month , treat insulin screening ) Patients history myocardial infarction , severe coronary artery disease clinically significant heart failure valvular defect last 6 month Patients consumptive disease , autoimmune disease , connective tissue disease Patients history type B C hepatitis Patients HIV hepatitis Patients clinically significant laboratory abnormality Patients receive drug know affect blood pressure medical treatment influence blood pressure Patients allergy contraindication angiotensin II receptor antagonist Female childbearing potential undergo hysterectomy postmenopausal Patients judge history alcohol drug abuse investigator Patients average weight &gt; +35 % &lt; 15 % Modified Metropolitan Life Insurance table Patients participate clinical trial 3 month Screening Patients judge inappropriate study investigator reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Fimasartan</keyword>
</DOC>